Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:36:30.108Z.
Calculation as of: 2026-10-06T13:36:30.108Z.
Quote observation: 2026-10-06T13:33:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 36850a73a8dd64042e14cdb756c8aff586d88f9314e30134a37dd84cc424cdb4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$4.54M
EV/FCF Ratio
N/A
TTM Avg
57.42x
3Y Avg
57.42x
5Y Avg
57.42x
Market Cap
$4.84M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $4.49M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.54M | N/A | 57.42x | 57.42x | 57.42x |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.49M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.36M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.63M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.80M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.82M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.84M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.07M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
